What is Moleculera Labs?
Moleculera Labs operates at the intersection of immunology and neurology, providing advanced testing solutions such as the Autoimmune Brain Panel. By identifying immune-mediated triggers for conditions like Alzheimer's disease, the company empowers healthcare providers to move beyond symptomatic treatment toward precision-based clinical interventions. Their market position is defined by a commitment to evidence-based medicine, targeting the growing demand for diagnostic tools that address treatment-resistant symptoms in complex patient populations. Through rigorous research and technological integration, Moleculera Labs is redefining the standard of care for immune-related brain disorders.
How much funding has Moleculera Labs raised?
Moleculera Labs has raised a total of $1.4M across 3 funding rounds:
Unspecified
$1.1M
Debt
$150K
Debt
$148K
Unspecified (2015): $1.1M with participation from i2E, Inc. and SeedStep Angels
Debt (2020): $150K led by PPP
Debt (2021): $148K supported by PPP
Key Investors in Moleculera Labs
i2E, Inc.
A specialized engineering and technical assistance firm that provides strategic project monitoring and environmental management solutions.
SeedStep Angels
A formalized group of angel investors focused on narrowing the capital gap for early-stage companies through coordinated due diligence and standardized investment processes.
PPP
Public-Private Partnership
What's next for Moleculera Labs?
With the recent influx of capital, Moleculera Labs is well-positioned to accelerate its clinical validation studies and broaden its commercial footprint. The strategic focus will likely shift toward enhancing the accessibility of their diagnostic services for healthcare professionals globally. As the company scales, the integration of its Autoimmune Brain Panel into standard clinical workflows will be paramount to achieving long-term market penetration. Furthermore, the firm is expected to leverage this financial runway to deepen its research pipeline, potentially uncovering new biomarkers that could expand its diagnostic portfolio into additional cardiovascular and neurodegenerative domains, thereby cementing its status as a leader in the precision medicine ecosystem.
See full Moleculera Labs company page
